The company plans to soon start the funding process for its oncology spin-off, Kaveri Therapeutics, which houses two specialised oncology programmes For the full story, visit the source.
Business
Lupin eyes $500 mn biosimilars revenue in medium term, to ramp capacity
The company plans to soon start the funding process for its oncology spin-off, Kaveri Therapeutics, which houses two specialised oncology programmes
By Sanket Koul· Business Standard· 22 days ago· 2 min read
This summary is sourced from Business Standard. Read the full article at:Business Standard